NFE2L2
NFE2L2 (Nuclear factor erythroid 2-related factor 2) is a transcription factor encoded by the NFE2L2 gene in humans. It plays a crucial role in the regulation of the expression of antioxidant proteins that protect against oxidative damage triggered by injury and inflammation.
Function[edit | edit source]
NFE2L2 is a member of the Cap 'n' Collar (CNC) family of transcription factors. It is primarily involved in the cellular response to oxidative stress. Under normal conditions, NFE2L2 is bound by KEAP1 (Kelch-like ECH-associated protein 1) in the cytoplasm, which targets it for ubiquitination and subsequent degradation by the proteasome. However, under oxidative stress, NFE2L2 is released from KEAP1, translocates to the nucleus, and binds to the Antioxidant Response Element (ARE) in the promoter regions of target genes. This binding initiates the transcription of various cytoprotective genes, including those involved in glutathione synthesis, NADPH regeneration, and the detoxification of reactive oxygen species (ROS).
Clinical Significance[edit | edit source]
Mutations and dysregulation of NFE2L2 have been implicated in several diseases, including cancer, neurodegenerative diseases, and chronic obstructive pulmonary disease (COPD). Overexpression of NFE2L2 has been observed in various types of cancer, where it contributes to the survival and proliferation of cancer cells by enhancing their antioxidant capacity. Conversely, loss of NFE2L2 function can lead to increased susceptibility to oxidative stress and related pathologies.
Interactions[edit | edit source]
NFE2L2 interacts with several proteins, including:
- KEAP1: Regulates the stability and activity of NFE2L2.
- MafG: Forms heterodimers with NFE2L2 to bind to ARE.
- CUL3: Part of the E3 ubiquitin ligase complex that targets NFE2L2 for degradation.
Research[edit | edit source]
Ongoing research is focused on understanding the precise mechanisms of NFE2L2 regulation and its role in disease. Therapeutic strategies aimed at modulating NFE2L2 activity are being explored for the treatment of diseases associated with oxidative stress.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
This transcription-related article is a stub. You can help WikiMD by expanding it.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
